TEG G | N(ct) | CM | COS | OS | STS | M | L | N(dp) | DM | RM | LI | LNI |
---|
Normo
(3.2-7.2) | 29.6% (21) | 21.7% (5) | 0% (0) | 33.3% (2) | 46.2% (6) | 41.7% (5) | 30% (3) | 29.1% (16) | 20% (2) | 0% (0) | 29.7% (11) | 100% (3) |
Hyper
(> 7.2) | 66.2% (47) | 69.6% (16) | 100% (7) | 66.7% (4) | 53.8% (7) | 58.3% (7) | 60% (6) | 67.3% (37) | 70% (7) | 80% (4) | 70.3% (26) | 0% (0) |
Hypo
(< 3.2) | 4.2% (3) | 8.7% (2) | 0% (0) | 0% (0) | 0% (0) | 0% (0) | 10% (1) | 3.6% (2) | 10% (1) | 20% (1) | 0% (0) | 0% (0) |
N
|
71
|
23
|
7
|
6
|
13
|
12
|
10
|
55
|
10
|
5
|
37
|
3
|
- In percentage is the proportion of patients for the given cancer type or disease progression group.
- TEG G = Coagulability measured by TEG G; N(ct) = Percentage and number of patients (in total) evaluated by cancer type; CM = Carcinoma located in the mammary gland; COS = Carcinoma located at other sites than the mammary gland; OS = Osteosarcoma; STS = Soft tissue sarcoma; M = Mastocytoma; L = Lymphoma; N(dp) = Percentage and number of patients (in total) evaluated by disease progression group; DM = Distant metastases; RM = Regional metastases; LI = Local invasive; LNI = Local non-invasive.